Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.68
VRTX's Cash to Debt is ranked higher than
60% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. VRTX: 1.68 )
VRTX' s 10-Year Cash to Debt Range
Min: 1.15   Max: 26.61
Current: 1.68

1.15
26.61
Equity to Asset 0.46
VRTX's Equity to Asset is ranked higher than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. VRTX: 0.46 )
VRTX' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.93
Current: 0.46

0.07
0.93
F-Score: 3
Z-Score: 10.87
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -119.41
VRTX's Operating margin (%) is ranked higher than
71% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. VRTX: -119.41 )
VRTX' s 10-Year Operating margin (%) Range
Min: -602.63   Max: 8.07
Current: -119.41

-602.63
8.07
Net-margin (%) -127.25
VRTX's Net-margin (%) is ranked higher than
70% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. VRTX: -127.25 )
VRTX' s 10-Year Net-margin (%) Range
Min: -630.27   Max: 2.1
Current: -127.25

-630.27
2.1
ROE (%) -61.64
VRTX's ROE (%) is ranked higher than
65% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. VRTX: -61.64 )
VRTX' s 10-Year ROE (%) Range
Min: -180.27   Max: 4.58
Current: -61.64

-180.27
4.58
ROA (%) -32.46
VRTX's ROA (%) is ranked higher than
71% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. VRTX: -32.46 )
VRTX' s 10-Year ROA (%) Range
Min: -58.14   Max: 1.51
Current: -32.46

-58.14
1.51
ROC (Joel Greenblatt) (%) -96.53
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. VRTX: -96.53 )
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1034.2   Max: 110.77
Current: -96.53

-1034.2
110.77
Revenue Growth (3Y)(%) -28.50
VRTX's Revenue Growth (3Y)(%) is ranked higher than
66% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. VRTX: -28.50 )
VRTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.4   Max: 130.2
Current: -28.5

-32.4
130.2
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VRTX Guru Trades in Q1 2014

Jim Simons 312,164 sh (New)
Steven Cohen 114,954 sh (New)
George Soros 10,000 sh (New)
John Burbank 2,872 sh (New)
Vanguard Health Care Fund 11,628,500 sh (+5.89%)
Pioneer Investments 1,195,955 sh (-1.70%)
» More
Q2 2014

VRTX Guru Trades in Q2 2014

Paul Tudor Jones 2,178 sh (New)
Ken Fisher 6,753 sh (New)
Vanguard Health Care Fund 11,807,500 sh (+1.54%)
Steven Cohen 934,700 sh (unchged)
George Soros Sold Out
John Burbank Sold Out
Jim Simons Sold Out
Pioneer Investments 850,152 sh (-28.91%)
» More
Q3 2014

VRTX Guru Trades in Q3 2014

Stanley Druckenmiller 146,600 sh (New)
Paul Tudor Jones 7,726 sh (+254.73%)
Vanguard Health Care Fund 11,807,500 sh (unchged)
Pioneer Investments 661,813 sh (unchged)
Ken Fisher 4,593 sh (-31.99%)
Steven Cohen 443,300 sh (-52.57%)
» More
Q4 2014

VRTX Guru Trades in Q4 2014

Andreas Halvorsen 764,200 sh (New)
Stanley Druckenmiller Sold Out
Pioneer Investments 647,257 sh (-2.20%)
Ken Fisher 4,378 sh (-4.68%)
Paul Tudor Jones 6,589 sh (-14.72%)
Vanguard Health Care Fund 9,808,860 sh (-16.93%)
Steven Cohen 16,500 sh (-96.28%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 25.64
VRTX's Forward P/E is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 25.64 )
N/A
P/B 25.80
VRTX's P/B is ranked lower than
53% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. VRTX: 25.80 )
VRTX' s 10-Year P/B Range
Min: 5.79   Max: 37
Current: 25.8

5.79
37
P/S 47.20
VRTX's P/S is ranked higher than
60% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. VRTX: 47.20 )
VRTX' s 10-Year P/S Range
Min: 4.47   Max: 80.48
Current: 47.2

4.47
80.48
EV-to-EBIT -41.23
VRTX's EV-to-EBIT is ranked higher than
64% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: -41.23 )
VRTX' s 10-Year EV-to-EBIT Range
Min: -49.4   Max: 4164.9
Current: -41.23

-49.4
4164.9
Current Ratio 4.20
VRTX's Current Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. VRTX: 4.20 )
VRTX' s 10-Year Current Ratio Range
Min: 2.23   Max: 20.55
Current: 4.2

2.23
20.55
Quick Ratio 4.12
VRTX's Quick Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. VRTX: 4.12 )
VRTX' s 10-Year Quick Ratio Range
Min: 2.23   Max: 20.55
Current: 4.12

2.23
20.55
Days Inventory 101.73
VRTX's Days Inventory is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 101.73 )
VRTX' s 10-Year Days Inventory Range
Min: 62.49   Max: 254.87
Current: 101.73

62.49
254.87
Days Sales Outstanding 47.77
VRTX's Days Sales Outstanding is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. VRTX: 47.77 )
VRTX' s 10-Year Days Sales Outstanding Range
Min: 25.75   Max: 106.15
Current: 47.77

25.75
106.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 219.70
VRTX's Price/Net Cash is ranked higher than
60% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. VRTX: 219.70 )
VRTX' s 10-Year Price/Net Cash Range
Min: 5.43   Max: 224.15
Current: 219.7

5.43
224.15
Price/Net Current Asset Value 140.30
VRTX's Price/Net Current Asset Value is ranked higher than
58% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. VRTX: 140.30 )
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 3.06   Max: 99.83
Current: 140.3

3.06
99.83
Price/Tangible Book 27.90
VRTX's Price/Tangible Book is ranked lower than
52% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. VRTX: 27.90 )
VRTX' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 75.48
Current: 27.9

2.9
75.48
Price/Median PS Value 2.60
VRTX's Price/Median PS Value is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. VRTX: 2.60 )
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 4.15
Current: 2.6

0.29
4.15
Earnings Yield (Greenblatt) -2.50
VRTX's Earnings Yield (Greenblatt) is ranked higher than
79% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. VRTX: -2.50 )
VRTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.5   Max: 5.3
Current: -2.5

-2.5
5.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VX1.Germany, VRTX.Mexico,
Vertex Pharmaceuticals Inc was incorporated in Massachusetts in 1989. The Company is engaged in the business of discovering, developing and commercializing small molecule drugs. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. The Company face competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 06 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 22 2012 
Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
Vertex Could Climb On New Drug, VX-222 Success Apr 22 2012 

More From Our Partners
Stock Market News for April 01, 2015 - Market News Apr 1 2015 - ZACKS

More From Other Websites
Is the FDA Worried About Vertex's New Drug? Mar 31 2015
Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List Mar 30 2015
11 promising drugs poised to be the next billion-dollar blockbusters Mar 27 2015
RBC Has 4 Biotech Stocks to Buy After Massive Pullback Mar 27 2015
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
One analyst is convinced the biotech stock plunge is 'misguided' Mar 26 2015
Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog Mar 24 2015
Vertex Treatment May Have High Risk of Failure, Analyst Suggests Mar 24 2015
Stock Market News for March 24, 2015 - Market News Mar 24 2015
Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Results Isn't The End Mar 23 2015
Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data Mar 23 2015
Major averages dropped into the close... Mar 23 2015
Why you shouldn’t read too much into the latest Vertex trial results Mar 23 2015
Vertex Tumbles As Cystic Fibrosis Data Disappoints Mar 23 2015
Vertex Pharmaceuticals (VRTX) Stock Falls Today on Cystic Fibrosis Drug Trial Data Mar 23 2015
Cramer's Mad Dash: Red-hot cyber play Mar 23 2015
Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations Mar 23 2015
Vertex Falls as VX-661 Cystic Fibrosis Drug Results Disappoint Mar 23 2015
Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in... Mar 23 2015
Booming biotech stocks: REGN, CELG & more Mar 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK